Please ensure Javascript is enabled for purposes of website accessibility

Why Ovid Therapeutics Stock Is Soaring Today

By Prosper Junior Bakiny – Jun 18, 2020 at 1:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small-cap biopharma got a nod from an analyst.

What happened?

Shares of Ovid Therapeutics (OVID -2.65%), a small-cap biopharmaceutical company, were up by 29.1% as of 12:51 p.m. EDT on Thursday, despite the company not reporting any news. The market is probably reacting to Ovid getting a buy rating from an analyst. 

So what

Michael Higgins, an analyst with Ladenburg Thalmann, reiterated a buy rating on Ovid's stock today. What's more, Higgins gave Ovid a price target of $20, which represents a significant upside from the company's previous close of $5.43. So it isn't surprising that investors rushed to purchase Ovid's stock, sending shares significantly higher. As of this writing, Ovid's stock is worth about $7.05.

Hand drawing an upward pointing graph on a board.

Image source: Getty Images.

Now what

It's important to take analyst recommendations with a grain of salt. Ovid currently has no products on the market and doesn't generate any revenue. The company does have several interesting pipeline candidates, however. In particular, Ovid's OV101 is an investigational treatment for a rare disorder called Angelman syndrome. This condition, usually diagnosed at an early age, causes such problems as delayed development, intellectual disability, severe speech impairment, and problems with movement and balance, among others.

There are currently no approved therapies for Angelman syndrome, and patients require intensive care. If OV101 turns out to be an effective treatment, not only will it be great news for Angelman sufferers and their families, but it could also be a lucrative opportunity for the company. In short, investors will want to keep a close eye on this healthcare stock.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ovid Therapeutics Inc. Stock Quote
Ovid Therapeutics Inc.
$1.84 (-2.65%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.